RNA-Sequencing-Based lncRNA Biomarker Profiling on Triple Negative Breast Cancer

: Basal-like triple-negative breast cancer (TNBC) is highly heterogeneous and lack of effective molecular targets for therapy. In this study, we developed the lncRNA signatures of TNBC as molecular biomarkers. RNA-sequencing in 12 paired breast cancer and adjacent tissues identified up-regulated and down-regulated lncRNAs of Basal subtype in contrast to Luminal A, Luminal B and HER2 subtypes. Additionally, Kaplan-Meier analysis revealed that high expression of lncRNA (ZEB1-AS1 and TMEM254-AS1) had a poor relapse-free survival rate (RFS), while high expression of lncRNA (LINC01087, LINC01122 and LINC00856) had a positive correlation with RFS. Furthermore, qRT-PCR analysis showed that the mRNA expressions of the ZEB1-AS1 and TMEM254-AS1 lncRNA were up-regulated in TNBC tissues, while the mRNA expression of lncRNA, including LINC01087, LINC01122 and LINC00856 were down-regulated in TNBC tissues. Taken together, our results elucidated that 5 novel lncRNAs, including ZEB1-AS1, TMEM254-AS1, LINC01087, LINC01122 and LINC00856 contributed to the progression of invasive TNBC. These lncRNAs could be molecular biomarkers for the development of TNBC treatment.